Tarsus Pharmaceuticals Net Worth

Tarsus Pharmaceuticals Net Worth Breakdown

  TARS
The net worth of Tarsus Pharmaceuticals is the difference between its total assets and liabilities. Tarsus Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Tarsus Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Tarsus Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if Tarsus Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Tarsus Pharmaceuticals stock.

Tarsus Pharmaceuticals Net Worth Analysis

Tarsus Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tarsus Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tarsus Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tarsus Pharmaceuticals' net worth analysis. One common approach is to calculate Tarsus Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tarsus Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tarsus Pharmaceuticals' net worth. This approach calculates the present value of Tarsus Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tarsus Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tarsus Pharmaceuticals' net worth. This involves comparing Tarsus Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tarsus Pharmaceuticals' net worth relative to its peers.

Enterprise Value

1.95 Billion

3436722.1B1.9B1.9B96%206%-10%5%100%
To determine if Tarsus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tarsus Pharmaceuticals' net worth research are outlined below:
Tarsus Pharmaceuticals generated a negative expected return over the last 90 days
Tarsus Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 182.95 M. Net Loss for the year was (115.55 M) with profit before overhead, payroll, taxes, and interest of 116.74 M.
Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (83.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2.
Over 91.0% of the company shares are owned by institutional investors
Latest headline from simplywall.st: Tarsus Pharmaceuticals Full Year 2024 Earnings Beats Expectations
Tarsus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tarsus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tarsus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
11th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Tarsus Pharmaceuticals Target Price Consensus

Tarsus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Tarsus Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   9  Strong Buy
Strong Buy66.7%Buy22.2%Hold11.1%Sell0.0%Strong Sell0.0%
Most Tarsus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Tarsus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Tarsus Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Tarsus Pharmaceuticals Target Price Projection

Tarsus Pharmaceuticals' current and average target prices are 43.55 and 66.00, respectively. The current price of Tarsus Pharmaceuticals is the price at which Tarsus Pharmaceuticals is currently trading. On the other hand, Tarsus Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Tarsus Pharmaceuticals Market Quote on 28th of February 2025

Low Price41.11Odds
High Price44.42Odds

43.55

Target Price

Analyst Consensus On Tarsus Pharmaceuticals Target Price

Low Estimate60.06Odds
High Estimate73.26Odds

66.0

Historical Lowest Forecast  60.06 Target Price  66.0 Highest Forecast  73.26
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Tarsus Pharmaceuticals and the information provided on this page.

Know Tarsus Pharmaceuticals' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Tarsus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tarsus Pharmaceuticals backward and forwards among themselves. Tarsus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tarsus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Amvescap Plc.2024-12-31
932.1 K
State Street Corp2024-12-31
916.9 K
Jpmorgan Chase & Co2024-09-30
880.3 K
Geode Capital Management, Llc2024-12-31
838.8 K
Macquarie Group Ltd2024-12-31
815.9 K
Artisan Partners Limited Partnership2024-12-31
691.3 K
Millennium Management Llc2024-12-31
644 K
Ikarian Capital, Llc2024-12-31
607.7 K
Ensign Peak Advisors Inc2024-12-31
570.1 K
Blackrock Inc2024-12-31
3.5 M
Rtw Investments, Llc2024-12-31
3.2 M
Note, although Tarsus Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Tarsus Pharmaceuticals' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.67 B.

Market Cap

1.97 Billion

Project Tarsus Pharmaceuticals' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.31)(0.33)
Return On Capital Employed(0.41)(0.43)
Return On Assets(0.31)(0.32)
Return On Equity(0.51)(0.49)
The company has Profit Margin (PM) of (0.63) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.37) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.37.
When accessing Tarsus Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tarsus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tarsus Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tarsus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tarsus Pharmaceuticals. Check Tarsus Pharmaceuticals' Beneish M Score to see the likelihood of Tarsus Pharmaceuticals' management manipulating its earnings.

Evaluate Tarsus Pharmaceuticals' management efficiency

Tarsus Pharmaceuticals has return on total asset (ROA) of (0.2346) % which means that it has lost $0.2346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5483) %, meaning that it created substantial loss on money invested by shareholders. Tarsus Pharmaceuticals' management efficiency ratios could be used to measure how well Tarsus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2025. Return On Capital Employed is likely to drop to -0.43 in 2025. At this time, Tarsus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 15.4 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 114 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 5.97  4.14 
Tangible Book Value Per Share 5.75  4.10 
Enterprise Value Over EBITDA(19.27)(20.24)
Price Book Value Ratio 9.27  9.74 
Enterprise Value Multiple(19.27)(20.24)
Price Fair Value 9.27  9.74 
Enterprise Value1.9 B1.9 B
The strategic initiatives led by Tarsus Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue
7.731
Revenue
183 M
Quarterly Revenue Growth
4.079
Revenue Per Share
4.865
Return On Equity
(0.55)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tarsus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tarsus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tarsus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Goodrich Katherine over a week ago
Acquisition by Goodrich Katherine of 10000 shares of Tarsus Pharmaceuticals at 46.51 subject to Rule 16b-3
 
Lin Elizabeth Yeu over three months ago
Acquisition by Lin Elizabeth Yeu of 27278 shares of Tarsus Pharmaceuticals subject to Rule 16b-3
 
Yarno Wendy L over three months ago
Acquisition by Yarno Wendy L of 3350 shares of Tarsus Pharmaceuticals subject to Rule 16b-3
 
Morrison Scott W over three months ago
Disposition of 1333 shares by Morrison Scott W of Tarsus Pharmaceuticals subject to Rule 16b-3
 
Link William J Phd over six months ago
Acquisition by Link William J Phd of 27116 shares of Tarsus Pharmaceuticals subject to Rule 16b-3
 
Yarno Wendy L over six months ago
Disposition of 3350 shares by Yarno Wendy L of Tarsus Pharmaceuticals subject to Rule 16b-3
 
Link William J Phd over six months ago
Acquisition by Link William J Phd of 3350 shares of Tarsus Pharmaceuticals subject to Rule 16b-3
 
Mottiwala Aziz over six months ago
Acquisition by Mottiwala Aziz of 12938 shares of Tarsus Pharmaceuticals subject to Rule 16b-3
 
Whitfield Dianne C. over six months ago
Disposition of 4463 shares by Whitfield Dianne C. of Tarsus PharmaceuticalsI subject to Rule 16b-3
 
Wahl Bryan over six months ago
Acquisition by Wahl Bryan of 12038 shares of Tarsus PharmaceuticalsI subject to Rule 16b-3
 
Azamian Bobak R. over six months ago
Acquisition by Azamian Bobak R. of 136947 shares of Tarsus PharmaceuticalsI at 35.5 subject to Rule 16b-3
 
Seshadri Neervannan over six months ago
Disposition of 4879 shares by Seshadri Neervannan of Tarsus PharmaceuticalsI at 30.6 subject to Rule 16b-3

Tarsus Pharmaceuticals Corporate Filings

8K
25th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13th of February 2025
Other Reports
ViewVerify
F3
15th of November 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
Tarsus Pharmaceuticals time-series forecasting models is one of many Tarsus Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tarsus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Tarsus Pharmaceuticals Earnings per Share Projection vs Actual

Tarsus Pharmaceuticals Corporate Management

Leonard JDChief OfficerProfile
Scott YoumansVice SalesProfile
Seshadri NeervannanChief OfficerProfile
Adrienne KempSenior CommunicationsProfile
Elizabeth MDChief DirectorProfile
Aziz MBAChief OfficerProfile

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…